Stem Cell Therapeutics reports positive results from its phase IIa clinical trial for stroke
Stem Cell Therapeutics Corp. (TSXV:SSS) is pleased to announce “positive” results from a phase IIa trial study for an acute stroke treatment.
The Calgary-based drug developer said the trial was designed to determine whether NTxTM-265 could be safely administered to a population of patients with acute stroke. In addition to the trial’s primary safety endpoint, a number of secondary endpoints are being studied to characterize early indicators of efficacy in patients receiving this novel stroke therapy. A review of the design of this clinical trial can be viewed at www.clinicaltrials.gov/ct/show/NCT00362414 and on SCT’s website under Dr. Steven Cramer’s poster presentation from the International Stroke Conference, Feb 2007.
Five patients who have had a moderate to severe stroke have been enrolled in the study to date. Four have safely completed a regimen initiated 24 to 48 hours after stroke with no drug-related serious adverse events.
A fifth study patient died before dosing was completed of causes unrelated to the treatment.
In early trading Tuesday on the TSX Venture Exchange, Stem Cell shares fell six cents to 76 cents, a drop of 7.3 per cent.
